Sleepiz secures EUR 800,000 in funding and joins the largest U.S. telemedicine organization
27.10.2022
ETH spinoff Sleepiz is joining the American Telehealth Association (ATA) after registering its Sleepiz One+ device with the FDA in July. Membership will give the company access to a broad network of tech vendors, investors, healthcare institutions, industry experts, and policymakers. The startup has also received funding of EUR 800,000 as part of a European research project. Sleepiz participated in Venture Kick in 2017 and made the TOP 100 Swiss Startup ranking in 2022.
 The compan's founders (from left to right): Max Sieghold (CFO), Soumya Dash (CEO), and Marc Rullan (CTO)
|
 |
The Swiss medtech startup Sleepiz registered Sleepiz One+— a device for the contactless measurement of respiration and heart rate—with the U.S. Food and Drug Administration (FDA) in July. Now, Sleepiz is joining the ATA, a broad-based network of leading academic institutions, technology solution providers, investors, and healthcare institutions dedicated to advancing telemedicine in the United States.
"Membership with the ATA gives us the opportunity to raise awareness of Sleepiz's technology in U.S. and global markets," said Robb LaChapelle, Sleepiz's vice president in the U.S. Sleepiz CEO Soumya Dash said, "This is an important step in bringing the benefits of our technology to patients, physicians and researchers, expanding the company's success into foreign markets."
Sleepiz also received EUR 800,000 from the European Active Assisted Leaving program to co-design a platform for the remote monitoring of nocturnal vital signs for the diagnosis, management, and prediction of chronic respiratory diseases in the elderly. The project aims to provide access to state-of-the-art healthcare for the elderly and chronically ill; it's carried out in collaboration with the Swiss Terz Foundation, In4Care Happy Aging from Belgium, and the leading medical informatics research group at Aalborg University in Denmark. Max Sieghold, co-founder of Sleepiz, said, "This partnership gives us the opportunity to warn patients about deteriorating health before it becomes acute."
Sleepiz One+ is one of the first respiratory monitoring devices to capture and record patient data during sleep without contact. The technology enables entirely new insights into patient health, as physicians no longer have to rely on random measurements, but gain access to continuous data. Physicians in the U.S. can prescribe Sleepiz One+ to their patients to measure their vital signs in the short and long term, providing greater insight into patients' physiological status. For patients, Sleepiz One+ provides a new and convenient way to take continuous measurements at home by simply placing a small device on their bedside table before bed.
Sleepiz participated in the Venture Kick program in 2017, winning CHF 10,000 to accelerate the startup's growth. The company was voted one of 2022's TOP 100 Swiss Startups by investors and experts. In 2020, it won the TOP 100 Public Vote.
The company's founders (from left to right): Max Sieghold (CFO), Soumya Dash (CEO), and Marc Rullan (CTO)
"Membership with the ATA gives us the opportunity to raise awareness of Sleepiz's technology in U.S. and global markets," said Robb LaChapelle, Sleepiz's vice president in the U.S. Sleepiz CEO Soumya Dash said, "This is an important step in bringing the benefits of our technology to patients, physicians and researchers, expanding the company's success into foreign markets."
Sleepiz also received EUR 800,000 from the European Active Assisted Leaving program to co-design a platform for the remote monitoring of nocturnal vital signs for the diagnosis, management, and prediction of chronic respiratory diseases in the elderly. The project aims to provide access to state-of-the-art healthcare for the elderly and chronically ill; it's carried out in collaboration with the Swiss Terz Foundation, In4Care Happy Aging from Belgium, and the leading medical informatics research group at Aalborg University in Denmark. Max Sieghold, co-founder of Sleepiz, said, "This partnership gives us the opportunity to warn patients about deteriorating health before it becomes acute."
Sleepiz One+ is one of the first respiratory monitoring devices to capture and record patient data during sleep without contact. The technology enables entirely new insights into patient health, as physicians no longer have to rely on random measurements, but gain access to continuous data. Physicians in the U.S. can prescribe Sleepiz One+ to their patients to measure their vital signs in the short and long term, providing greater insight into patients' physiological status. For patients, Sleepiz One+ provides a new and convenient way to take continuous measurements at home by simply placing a small device on their bedside table before bed.
Sleepiz participated in the Venture Kick program in 2017, winning CHF 10,000 to accelerate the startup's growth. The company was voted one of 2022's TOP 100 Swiss Startups by investors and experts. In 2020, it won the TOP 100 Public Vote.
"Being in the Top 100 startups gives visibility and recognition to Sleepiz AG within the Swiss Startup ecosystem," CEO Soumya Dash said. "Also, it’s a morale booster for the team. Being a part of the Venture Kick program early on helped me to fail fast and understand most, if not all, aspects of being a founder."
The company's founders (from left to right): Max Sieghold (CFO), Soumya Dash (CEO), and Marc Rullan (CTO)
Additional Links
- Sleepiz raises CHF 4.4 million in Series A round to expand its portfolio
- Sleepiz AG secures USD 1 million to create the future of sleep apnea diagnostics
- Sleepiz raises million CHF 6,2 in Series A financing round to launch its sleep apnea monitor in foreign markets
- Check out the four Venture Kick winners of stage 1